Navigation Links
Anadys Announces Issuance of U.S. Patent Covering Setrobuvir (ANA598)
Date:6/1/2011

, setrobuvir (ANA598) is being tested in combination with Pegasys® and Copegus® in both treatment-naive patients and patients who failed a prior course of therapy with interferon and ribavirin.  Dosing is underway and approximately 275 patients are expected to be enrolled in the study.  The primary endpoint of the study is Sustained Virological Response 24 weeks after patients complete treatment, known as SVR24.  The Company expects to receive antiviral response data through 12 weeks for all patients, including the 8 week timepoint used for response-guided therapy in treatment-naive patients, in the third quarter of 2011.  Antiviral response data through 24 weeks are expected in the fourth quarter of 2011.  

Prior Clinical and Preclinical Profile of Setrobuvir (ANA598)

In an earlier Phase IIa study, setrobuvir (ANA598) demonstrated potent antiviral activity, as well as good safety and tolerability in combination with interferon and ribavirin through 12 weeks of dosing in treatment-naive genotype 1 HCV patients.  In a completed Phase I study, setrobuvir demonstrated potent antiviral activity in a three day monotherapy study in treatment-naive genotype 1 patients.  To date, setrobuvir has demonstrated an excellent resistance profile in HCV patients.

Setrobuvir (ANA598) has also been characterized in a variety of preclinical studies.  In completed long-term chronic toxicology tests in both rats and monkeys, the No Observed Adverse Effect Level, or NOAEL, was 1000 mg/kg, the highest dose tested.  Data from preclinical models of antiviral activity have laid the foundation for clinical investigation of setrobuvir (ANA598) in DAA combinations.  In particular, synergistic antiviral activity in vitro was observed when setrobuvir (ANA598) was combined with a number of approved or investigational HCV agents, and in vitro combinations of setrobuvir (ANA598) with other DAAs from
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Reports First Quarter 2011 Financial Results and Highlights
2. Anadys Pharmaceuticals Appoints Barry Labinger to Its Board of Directors
3. Anadys Pharmaceuticals to Present at the Cowen & Company Healthcare Conference
4. Anadys Pharmaceuticals to Report Fourth Quarter and Year-end 2010 Financial Results
5. Anadys Pharmaceuticals to Present at the Bio CEO & Investor Conference
6. Anadys Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
7. Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients
8. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
9. Anadys Pharmaceuticals to Report Third Quarter 2010 Financial Results
10. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
11. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... , May 24, 2013 In accordance with ... and Rule 14e-1 of the United States Exchange Act, Echo ... original offer for Elan Corporation (NYSE: ELN). Background ... ("Royalty Pharma") made an offer for the entire of the ... plc ("Elan") (the "Original Offer").  On 20 ...
(Date:5/24/2013)... The potential of the pulmonary route as ... has been receiving undeniable attention with the recent advances ... crucial formulation considerations for orally inhaled products together with ... in the efficiency of pulmonary delivery, and great strides ... techniques and devices in recent years. With ...
(Date:5/23/2013)... SHENYANG, CHINA , May 24, 2013 /PRNewswire/ ... ("3SBio" or the "Company"), a leading ... developing, manufacturing and marketing biopharmaceutical products, announced today ... (the "EGM"), the Company,s shareholders voted in favor ... previously announced agreement and plan of merger dated ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
... 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX ... company focused on researching, developing, manufacturing and marketing biopharmaceutical ... second quarter 2011 results after the NASDAQ stock market ... Eastern). Following the earnings announcement, 3SBio,s ...
... RIVER EDGE, N.J., July 21, 2011 Nephros, Inc. ... device company developing and marketing filtration products for therapeutic ... the Company has received 510k clearance from the U.S. ... SSU ultrafilters to filter out biological contaminants from water ...
Cached Medicine Technology:3SBio Inc. Schedules Unaudited Second Quarter 2011 Results 2Nephros Receives 510k Approval to Market Additional Ultrafiltration Products 2Nephros Receives 510k Approval to Market Additional Ultrafiltration Products 3Nephros Receives 510k Approval to Market Additional Ultrafiltration Products 4
(Date:5/25/2013)... (PRWEB) May 25, 2013 Today, Zane ... insurance marketplaces . Zane Benefits, which provides comprehensive and ... the leader in defined contribution plans and ... the October 1, 2013 open enrollment of the Health ... of the Marketplaces is "Choice, Competition and Clout for ...
(Date:5/25/2013)... Imagine running the air conditioner with the windows open all ... energy! If the home has a folding pull-down attic stair, ... may be just what is occurring in the home every ... in the form of higher energy bills. Drafts are the ... , Drafts occur through the small cracks around doors, windows, ...
(Date:5/25/2013)... NYC,NY (PRWEB) May 25, 2013 Dr. ... only non-invasive procedure FDA-approved to lift skin on the neck, ... available at her practice, Medical Aesthetics. , Ultherapy is a ... body’s own natural healing process to lift the skin over ... the first time, to see and then treat the deepest ...
(Date:5/25/2013)... Communities of Distinction TV announces May ... largest media market in the United States with almost three ... in Texas and a major convention city. Ft. Worth is ... it is home to many major museums. Both cities offer ... the arts. Residents and locals will be able to watch ...
(Date:5/25/2013)... 25 (HealthDay News) -- Many viruses and parasites that ... leptospirosis -- a bacteria-borne illness than can result in ... dog parks, according to a veterinarian. These ... even the air, said Dr. Susan Nelson, a clinical ... "Many of these serious diseases can be fatal, even ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on the Health Insurance Marketplaces 2Health News:Zane Benefits Publishes New Information on the Health Insurance Marketplaces 3Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 2Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 3Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 4Health News:Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ 2Health News:Communities of Distinction TV Presents May Air Dates for Dallas-Ft. Worth, Texas 2Health News:Hidden Dangers Dog Dog Parks 2
... announces the launch of a brand new internet-based ... Fintan Walton, CEO, PharmaVentures, says, ‘This show, the ... the pharmaceutical and biotechnology sectors with insightful analysis ... It gives exclusive access to topical interviews with ...
... are no effective in encouraging students to adopt safe ... has found. The study, conducted by Mexican researchers has ... the transmission of AIDS/HIV and other sexually transmitted infections. ... importance of condom use and refraining from sex (abstinence), ...
... State Auditor Pat Anderson says that the taxpayers are in ... state has not set aside anything in term of their ... challenge that state and local governments are yet to face. ... help pay pension benefits but nothing when it comes to ...
... In a breakthrough and an answer to so many people’s ... eat and overeat. //, ,These scientists studied brain ... brains which tend to be especially sensitive to ads featuring ... areas are greatly stimulated by food images it is likely ...
... Organization (WHO) has praised the way in which the two ... but criticized china.// China threatened the rest of the world ... critical early months. ,In its book WHO talks ... also talks about the way by which Taiwan handled the ...
... affects 300, 000 Americans each year. A problem with such ... time they reach an emergency room.// Among these cases, 10 ... with 64 percent having significant disability. Around 5 percent will ... presented at the 2006 Society for Academic Emergency Medicine Annual ...
Cached Medicine News:Health News:PharmaVentures Exploits Fastest Growing Media Channel to Launch First Pharmaceutical Business Television Show 2Health News:The persistent urge to eat: Loose control!!! 2Health News:Prompt Diagnosis Could Be Life-Saving In Mini-Strokes 2
The Shandon Linistain SLS Linear Stainer is an economical mid-size linear stainer for staining procedures that do not require heat....
... is a manual rotary microtome for routine ... flywheel designed to address repetitive stress injury. ... debris tray, organizer storage tray and a ... standard and may be disengaged at the ...
... remote monitoring service allows the the ... monitored from any location via modem ... enhances preventive maintenance capabilities. Thermo ... unit (with your permission) from their ...
... Tissue Processor is the most ... reagents today. It comes equipped ... to provide benefits of safety, ... reagent cost savings and quality ...
Medicine Products: